Antibodies Market Size was valued at USD 235.2 Billion in 2022. The antibodies market industry is projected to grow from USD 267.65 Billion in 2023 to USD 752.86 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.80% during the forecast period (2024 - 2032). Increased increasing focus of biopharmaceutical and biotechnology companies and increase in focus on research and development are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The antibodies market is witnessing a significant trend towards the dominance of monoclonal antibodies (mAbs). Monoclonal antibodies are engineered to target specific proteins, offering precision in treating various diseases, including cancers and autoimmune disorders. The increasing approval of novel mAbs for therapeutic applications showcases a growing reliance on this technology. Advancements in antibody engineering techniques, such as bispecific antibodies and antibody-drug conjugates, further enhance their therapeutic potential, driving a transformative trend in the antibodies market. This factor drives the Market CAGR.
Additionally, the antibodies market is experiencing a surge in demand for therapeutic antibodies, fueled by their effectiveness in treating various diseases. Therapeutic antibodies play a pivotal role in personalized medicine, targeting specific molecules involved in diseases like cancer and inflammatory conditions. The growing understanding of immune responses and the development of recombinant DNA technology have accelerated the production of therapeutic antibodies. This trend is characterized by an expanding pipeline of antibody-based therapeutics and increased collaborations between pharmaceutical companies and biotech firms to bring innovative antibody treatments to the market.
A notable trend in the antibodies market revolves around the increasing use of antibodies in diagnostics, particularly in the realm of precision medicine. Antibodies are vital components in diagnostic assays, facilitating the detection of specific biomarkers associated with diseases. The advent of personalized medicine has propelled the demand for diagnostic antibodies tailored to individual patient profiles. The development of multiplex assays and point-of-care diagnostics employing antibodies allows for efficient disease diagnosis and monitoring. This trend aligns with the broader shift towards precision medicine, where targeted therapies and diagnostics based on individual patient characteristics are becoming increasingly prevalent.
For instance, In April 2021, Xencor commenced its Phase I clinical trial of its newly engineered Interleukin-2 (IL-2) Fc cytokine and XmAb564 antibody therapeutics designed for developing the treatment of patients with autoimmune diseases. Novel biosimilar antibody manufacturers are slashing their prices to compete with branded antibody manufacturers, especially in the European market. Thus, driving the antibodies market revenue.
The antibodies market segmentation, based on Disease Indication includes Cardiovascular Diseases, CNS Disorders, Cancer, and Autoimmune Disorders. The cancer stands as the dominating disease indication, reflecting its prevalence and the growing demand for targeted therapies in oncology. The dominance of cancer-related antibodies is attributed to the continuous research and development efforts to introduce innovative and effective antibody-based treatments for various types of cancer. Conversely, autoimmune disorders emerge as the fastest-growing category, fueled by a surge in autoimmune-related conditions and the escalating need for advanced and specific antibody therapies to address these complex diseases.
The antibodies market segmentation, based on Product Type, includes Monoclonal Antibodies, Polyclonal Antibodies, and Antibody-drug Complexes. Monoclonal antibodies category dominates the product type category due to their precision and specificity in targeting particular antigens. Monoclonal antibodies are widely utilized in therapeutic applications, diagnostics, and research, contributing to their sustained dominance. On the other hand, antibody-drug complexes emerge as the fastest-growing category, driven by the increasing focus on developing antibody-drug conjugates (ADCs) for targeted cancer therapy. The demand for innovative treatment modalities that combine the specificity of antibodies with the cytotoxic potential of drugs propels the rapid growth of antibody-drug complexes in the market.
The antibodies market segmentation, based on End User, includes Hospitals, Long-term Care Facilities, and Research Institutes. Hospitals category dominate the end-user category, as they serve as primary healthcare institutions with extensive diagnostic and therapeutic applications of antibodies. The dominance of hospitals is attributed to the widespread use of antibodies in various medical treatments, diagnostics, and research within hospital settings. Conversely, research institutes emerge as the fastest-growing category, driven by the escalating demand for antibodies in cutting-edge research activities, particularly in the fields of biotechnology and life sciences.
Figure1: Antibodies Market, by Distribution channel,2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American antibodies market area will dominate this market, owing to robust biopharmaceutical industry with a significant focus on research and development will boost market growth in this region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure2: ANTIBODIES MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe antibodies market accounts for the second-largest market share due to the well-developed healthcare and pharmaceutical sector, with a strong emphasis on research and innovation. Further, the German antibodies market held the largest market share, and the UK antibodies market was the fastest growing market in the European region
The Asia-Pacific Antibodies Market is expected to grow at the fastest CAGR from 2024-2032. This is due to rising prevalence of various diseases, creating a demand for advanced therapeutic solutions, including antibodies. Moreover, China’s antibodies market held the largest market share, and the Indian antibodies market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the antibodies market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, antibodies industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the antibodies industry to benefit clients and increase the market sector. In recent years, the antibodies industry has offered some of the most significant advantages to medicine. Major players in the antibodies market, including Novartis AG,F. Hoffmann-La Roche AG, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Amgen Inc., and others, are attempting to increase market demand by investing in research and development operations.
Novartis is a Swiss multinational pharmaceutical company headquartered in Basel, Switzerland. Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has grown to become one of the largest and most diversified pharmaceutical companies globally. The company operates in various segments, including Pharmaceuticals, Alcon (eye care), Sandoz (generic pharmaceuticals), and Innovative Medicines. Novartis is renowned for its commitment to research and development, focusing on innovative therapies in areas such as oncology, cardiovascular, neuroscience, immunology, and more. With a global presence and a portfolio of cutting-edge medicines, Novartis plays a crucial role in shaping the pharmaceutical industry. On June 11, 2021, Novartis published its new Phase II data of an investigational oral treatment iptacopan, developed for treating paroxysmal nocturnal hemoglobinuria (PNH). The study indicated that during 12 weeks of iptacopan monotherapy treatment, no unexpected safety issues were reported which led to rapid and durable transfusion-free improvement of hemoglobin levels in the majority of patients.
Johnson & Johnson (J&J) is a multinational conglomerate and one of the largest healthcare companies globally. Founded in 1886 in New Brunswick, New Jersey, USA, by the Johnson brothers and Robert Wood Johnson, J&J operates in three main segments: Pharmaceuticals, Medical Devices, and Consumer Health. The company is known for its diverse range of products, including prescription drugs, medical devices, and consumer healthcare products. Some well-known brands under the Johnson & Johnson umbrella include Band-Aid, Neutrogena, Tylenol, and Johnson's Baby. J&J is committed to advancing health and well-being through innovation and addressing healthcare challenges worldwide. In August 2020, Johnson & Johnson entered into a final agreement to acquire Momenta Pharmaceuticals Inc. for around US$ 6.5 Billion. Momenta Pharmaceuticals Inc. is a market leader in developing novel therapies for immune-mediated diseases.
In December 2023, Danaher bought Abcam for $5.7 billion to strengthen its product portfolio and expand the customer base. The bullish approach is expected to drive the growth of the research antibodies market over a forecast period.
In June 2023, Cell Signaling Technology (CST) partnered with Lunaphore. It aimed at allowing CST antibodies on the COMET platform through Lunaphore so as to enhance fully automated spatial biology.
In July 2023, Lunaphore was acquired by Bio-Techne Corporation in July 2023. This business resolution was made to grow the spatial biology leadership of companies in translational and clinical research.
In June 2023, Cell Signaling Technology (CST) partnered with Lunaphore. It aimed at allowing CST antibodies on the COMET platform through Lunaphore so as to enhance fully automated spatial biology.
In February 2023, Cell Signaling Technology entered into a partnership with Bio-Techne. This transaction was all about adding Simple Western validation from Bio-Techne to CST antibodies.
March 2022: Sanofi, a pharmaceutical and healthcare company, and Seagen Inc., a biotechnology company, announced a collaboration agreement, to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets.
| Report Attribute/Metric | Details |
| Market Size2022 | USD 235.2 Billion |
| Market Size 2023 | USD 267.65 Billion |
| Market Size2032 | USD 752.86 Billion |
| Compound Annual Growth Rate (CAGR) | 13.80% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Disease Indication, Product Type, End User and Region |
| Geographies Covered | North America, Europe, AsiaPacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Novartis AG,F. Hoffmann-La Roche AG, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Amgen Inc |
| Key Market Opportunities | · Increased increasing focus of biopharmaceutical and biotechnology companies |
| Key Market Dynamics | · Increase in focus on Research and Development |
Frequently Asked Questions (FAQ) :
The antibodies market size was valued at USD 235.2 Billion in 2022.
The global market is projected to grow at a CAGR of 13.80% during the forecast period, 2024-2032.
North America had the largest share in the global market
The key players in the market are Novartis AG,F. Hoffmann-La Roche AG, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Amgen Inc.
The Cancer category dominated the market in 2022.
The Hospitals based had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
